Q-omics provides the consensus-scored SHTN1 profile across patient tissues and cancer cell-line models. SHTN1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SHTN1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SHTN1 protein abundance shows 22,847 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, HNSC, and GBM as cancer lineages where SHTN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHTN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHTN1 survival associations across molecular data types. SHTN1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHTN1 RNA expression–survival associations across cancer types. High SHTN1 expression shows unfavorable associations in BLCA, ACC, UVM, KICH and LUAD, but favorable associations in READ. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SHTN1 RNA expression.
This table summarizes SHTN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SHTN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHTN1 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, KIRP, BLCA and STAD. The HNSC box plot shows higher SHTN1 RNA expression in tumor versus normal tissue (log2 FC = +1.014, t-test p < 0.001).
This table shows molecular features associated with SHTN1 in patient tissues and cancer cell lines. In patient samples, SHTN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SHTN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
